Filter posts

“Health Care’s Big Spending Mismatch”

This week, Axios reported on new data that shows “the health care services that rack …

WSJ: Drug Importation is “Impractical, Unsafe and Unlikely” to Lower Prices

This week, Editorial Board writers for The Wall Street Journal examined a policy proposal in …

Greenwood: In Pharma Value Chain, PBMs Manage to Benefit

Writing for The Hill, BIO’s President and CEO Jim Greenwood offered praise to the Senate Finance …

A Few Questions as PBMs Have Their Day on Capitol Hill

Tomorrow, the Senate Finance Committee will examine the role of pharmacy benefit managers (PBMs) in …

Dr. Emanuel Misses the Mark with Latest Industry Attack

Writing for The Atlantic, Dr. Ezekiel Emanuel accuses the biopharmaceutical industry of being “deceptive” when …

Oncologist Warns of IPI’s Potentially Dangerous Implications

Writing for Morning Consult, Dr. Lucy Langer, a clinical oncologist with Compass Oncology in Portland, …

Peter Pitts Examines the Role of PBMs and their Deceptive Tactics

A piece by Peter J. Pitts, a former FDA Associate Commissioner and President of the …

Kentucky Officials Expose PBMs for Gaming the System

While many were watching the drug pricing debate unfold on Capitol Hill, the Kentucky Cabinet …

Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical ...

In his State of the Union address, President Trump called on Congress to “do more” …

Health Care in Focus as President Trump Addresses the Nation

In his State of the Union address, President Trump described the need to rein in …